US20200032318A1 - Detection method and device - Google Patents
Detection method and device Download PDFInfo
- Publication number
- US20200032318A1 US20200032318A1 US16/592,992 US201916592992A US2020032318A1 US 20200032318 A1 US20200032318 A1 US 20200032318A1 US 201916592992 A US201916592992 A US 201916592992A US 2020032318 A1 US2020032318 A1 US 2020032318A1
- Authority
- US
- United States
- Prior art keywords
- detection
- objects
- pcr
- whole blood
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims description 40
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000011159 matrix material Substances 0.000 claims abstract description 39
- 239000008280 blood Substances 0.000 claims abstract description 34
- 210000004369 blood Anatomy 0.000 claims abstract description 33
- 239000012634 fragment Substances 0.000 claims abstract description 16
- 238000011895 specific detection Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 39
- 244000052769 pathogen Species 0.000 claims description 28
- 239000000523 sample Substances 0.000 claims description 28
- 238000003752 polymerase chain reaction Methods 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000007399 DNA isolation Methods 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 4
- 238000007403 mPCR Methods 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000013024 dilution buffer Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000011535 reaction buffer Substances 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000011896 sensitive detection Methods 0.000 abstract description 3
- 239000011324 bead Substances 0.000 description 16
- 206010014665 endocarditis Diseases 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000009640 blood culture Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 208000037815 bloodstream infection Diseases 0.000 description 2
- 210000005266 circulating tumour cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 241001024600 Aggregatibacter Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100188555 Arabidopsis thaliana OCT6 gene Proteins 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241000207210 Cardiobacterium hominis Species 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 241000589014 Kingella kingae Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Definitions
- the “Cell Collector” from Gilupi, Potsdam is a device for enriching circulating tumour cells in vivo on the surface of a metal rod.
- MagNA Lyser beads from Roche Diagnostics, Mannheim, are ceramic magnetobeads for the mechanical disruption of cells and the subsequent enrichment of the DNA they contain.
- the beads of the ⁇ MACS series from Miltenyi, Bergisch-Gladbach are used for the enrichment of DNA and RNA from cells. This procedure may increase the sensitivity and specificity of the detection. However, these procedures are time consuming and they usually require much equipment.
- these methods are usually based on individual molecular target structures that are characteristic of the target objects. This means that target objects or their molecules are specifically enriched depending on the capture structures used, for example antibodies. For example, the use of antibodies to enrich a particular pathogen species may not enrich other simultaneously occurring pathogens.
- non-molecular state of the art methods comprise blood culture, in which the pathogens are cultivated for a few hours or even days before detection in order to increase the sensitivity of the detection, are therefore often preferred.
- This cultivation can also be preceded by molecular detection.
- these cultivation methods are time-consuming, labor-intensive, and problematic in that not all pathogens in the blood culture can be cultivated or multiplied and detected equally (Striebel, 2014, Thalhammer et al, 2016). This results in limited sensitivity or specificity.
- FIG. 1 Representation of the general workflow for the purification of matrix objects and detection of target structures.
- FIG. 2 Representation of the proposed workflow according to the invention, for enrichment of matrix objects and detection of pathogens.
- FIG. 3 Representation of the proposed workflow according to the invention in detail.
- the invention concerns a method and a device for enriching cells, cell fragments and molecules from whole blood for a specific detection of at least one population of cells, cell fragments or molecules contained therein.
- Cells according to the invention are biological cells, eukaryotic and prokaryotic cells, nucleated or non-nucleated, as well as unicellular organisms, and multicellular organisms.
- Cell fragments according to the invention are parts of cells, including cell wall components, organelles, membrane components, blood platelets and micelles, as well as viruses.
- Molecules according to the invention include macromolecules including proteins, peptides, and oligonucleotides such as DNA and RNA, or lipids, carbohydrates, and small molecules.
- Target objects Cells or viruses to be detected are hereinafter referred to as target objects.
- Pathogens such as bacteria, fungi, protozoa and viruses may also be target objects.
- fetal cells in the maternal blood or circulating tumour cells may also be targets.
- the detection method may aim at detecting the DNA, RNA or antigens of the target objects, fragments of the cells, or the whole cells. To simplify matters, these detection methods are also referred to below as detection method of target objects.
- Matrix cells comprise in particular the various types of immune cells (lymphocytes) as well as erythrocytes and cell fragments such as platelets.
- Methods for detecting target objects, their molecules and in particular their DNA from whole blood comprise, for example, molecular biological techniques such as PCR (polymerase chain reaction) or arrays, recently also sequencing, NMR or mass spectroscopy.
- the primary object of the current invention is to detect a wide spectrum of target objects including their molecules simply, quickly and yet sensitively and specifically from whole blood.
- pathogen infections in whole blood just a few pathogens (3-1000 pathogens/ml whole blood) can be reliably, specifically and sensitively detected by PCR by enriching matrix objects, in particular immune cells or individual immune cell populations, sample processing, DNA isolation and subsequent PCR. Possibly a specific binding of the matrix objects to target objects such as pathogens or specific phagocytosis processes are associated with this. These effects could increase the ratio of pathogen to eukaryotic material and thus reduce the background signal in some detection methods, especially PCR (Loonen et al, 2013).
- the matrix objects can be enriched using particles that bind specifically or non-specifically to specific matrix objects.
- the binding of the particles to the matrix objects can be mediated by coating or coupling the particles with capture molecules, in particular antibodies or other proteins, peptides or aptamers.
- the particles may have other properties such as magnetic, acoustic or dielectric properties that allow them to be directly enriched or isolated.
- the size of particles can lie within a specific range so that they can be enriched with a particle filter.
- the enrichment can also be carried out chromatographically, even if the device requires more complex equipment.
- the matrix objects flow past the immobilized beads, especially beads with capture molecules, with which the surface of a flow device is coated.
- the described beads can also be used as packing material of a chromatographic column.
- An additional centrifugation step can further improve the enrichment, but increases the complexity of the process. Therefore it can be advantageous to carry out the enrichment without centrifugation step.
- the enrichment can also be done with a flow cytometer.
- Matrix objects that can be enriched according to the invention include leukocytes, in particular monocytes, macrophages, B cells, T cells, NK cells, eosinophilic, basophilic and neutrophil granulocytes, dendritic cells, but also erythrocytes.
- Matrix objects can also be natural cell fragments, including platelets, or cell debris caused by mechanical or chemical action or biological processes such as apoptosis. It may be preferable to enrich more than one population of matrix objects, in particular by using particles or beads specific to several matrix objects or different particles specific to one type of matrix object. However, the accumulation of the entire lymphocyte spectrum is apparently unfavourable (Banada et al., 2012).
- the enrichment of the immune cells of the example of an embodiment of the invention is advantageous, for example, via antibodies that are bound to a carrier system (especially particles, especially beads, or solid matrices). Similarly advantageous is to perform the enrichment in fluidic or microfluidic systems, in which the immune cells or particles are enriched by forces or energy input, especially by acoustic or dielectrophoretic effects in the liquid flow, or in the flow cytometer.
- nucleic acids in particular DNA and RNA of the target objects and in particular the pathogens.
- Various state-of-the-art processes are available for this purpose, including trizollysis, other chemical methods and mechanical digestion. Subsequent precipitation of the DNA or RNA with ethanol and purification via columns are often advantageous.
- PCR isothermal amplification, sequencing or array-based methods are suitable for the detection of DNA or RNA.
- multiplex and single PCR can be distinguished in PCR, the latter of which is particularly advantageous because it enables a particularly simple procedure. This makes individual PCR particularly suitable for carrying out the procedure at the point of care and detecting specific pathogens and resistance indicators or genes.
- the invention also includes a device for isolation, optionally supplemented by the detection of target objects.
- a cartridge system comprises devices for sample introduction, storage locations for different wash buffers, storage locations for a bead-antibody system for binding specific matrix objects, in particular immune cells, as well as a possibility for lysis of isolated matrix objects, and optionally a device for extracting the RNA or DNA.
- the antibody bead system is added to the whole blood, washed with a wash buffer, the antibody bead system with bound matrix objects is isolated via a sieve system or magnetically, mixed with cell lysis buffer and the precipitated DNA removed.
- a fast and simple enrichment of the matrix objects as well as lysis and DNA isolation is carried out in an almost closed container, thus reducing the risk of contamination of the sample with foreign DNA.
- RNA or DNA remains in the cartridge system and is not removed. Instead, PCR is performed through a window in the cartridge or with integrated heating and detection elements inside the cartridge. It then contains another storage location for the PCR reagents.
- the isolated DNA is applied directly to a PCR analysis plate, which contains all chemicals for the analysis of various pathogens in a standardised form.
- This plate can be produced as multiplex PCR or as a set of single PCR performed in parallel.
- the isolated DNA from the cartridge can be applied manually and especially with a pipette or directly from the cartridge via a special dosing system.
- the process according to the invention, the device according to the invention, and the application kit according to the invention can be used for the detection of a variety of diseases and physiological conditions. These include the following examples:
- SIRS Systemic Inflammatory Response Syndrome
- Endocarditis also requires the rapid detection of pathogens in the blood for a therapeutic decision.
- the conditions for blood culture are considered particularly demanding and time-consuming. (Durack et al. 1994).
- Pathogens that grow particularly slowly in the laboratory but are relevant for about 3% of endocarditis cases are grouped in the HACEK group ( Aggregatibacter aphrophrophilus, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens , and Kingella kingae ).
- bacteria can be detected in the urine after a few days.
- State-of-the-art blood cultures are recommended, especially for nocosomial pneumonia and pneumonia caused by air conditioning systems, which is becoming increasingly common.
- the method according to the invention also offers the advantage of a faster detection of these infections.
- Zoonoses are infections with a wide range of manifestations, some of which are diagnosed using blood cultures, some of which last 4-6 weeks, for example when brucellosis is suspected.
- the method according to the invention also offers the advantage of a faster detection of these infections.
- the ingenious method also has potential applications for viral diseases, especially for detection of HIV in pregnant women, where a reliable diagnosis is particularly important in order to initiate measures to prevent transmission to the child.
- the invention-based method can also be used in the quality and follow-up of CAR-T therapies (Chimeric Antigen Receptor T-cell therapies).
- the procedure according to the invention comprises the following steps: First, one or more blood samples are taken from the patient, the coagulation of which is avoided in the EDTA/citrate buffer. Beads, for example anti-CD14 beads from pluriSelect, are added to this sample to bind the matrix objects, for example all CD14-bearing cells such as monocytes and macrophages.
- Beads for example anti-CD14 beads from pluriSelect, are added to this sample to bind the matrix objects, for example all CD14-bearing cells such as monocytes and macrophages.
- the beads are then separated by a sieve, for example with the Cell Strainer from pluriSelect.
- the sample with the enriched matrix objects is subjected to DNA lysis in a subsequent step (e.g. tricol precipitation).
- the sample is then distributed to several sample vessels, for example wells of a-microtiter plate suitable for qPCR. These wells already contain reagents for a qPCR, including primers for a known sequence which are different for each well, and which serves to identify a target object or its resistance to therapy via a genetic marker. Subsequently a single qPCR is performed. Quantification of the signal makes it possible to determine which target objects or resistance genes are present in the sample.
- the invention also comprises an application kit for isolation and analysis of cells, cell fragments and molecules, consisting of at least
- FIG. 1 shows the process sequence according to the method of invention. Matrix objects associated with target structures are specifically isolated from a sample. After processing the samples, the actual detection method of the target structures is carried out.
- FIG. 2 shows a specific procedure according to the invention for the detection of pathogens in blood.
- EDTA whole blood is introduced into the cartridge system according to invention, in which the sample is incubated with CD14 beads, washed with buffer and transferred via a sieve system isolating the beads together with trapped monocytes/macrophage (matrix objects) and the pathogens (target objects) contained therein.
- Cell lysis and isolation/purification of the DNA is then carried out before the DNA sample is transferred with pipettes from the cartridge into the PCR well plates according to the invention. These plates already contain all the chemicals required for PCR in lyophilized form; the polymerase is added to the well plate together with the DNA sample. Subsequently, PCR and thus specific detection of the pathogens is performed.
- the enrichment of the target objects with the matrix objects or the depletion of non-target objects allows for an increased sensitivity and specificity of the detection method compared to the state of the art; employing the workflow according to the invention and the cartridge system leads to fast results using standard laboratory equipment.
- FIG. 3 shows the procedure exemplified in FIG. 2 , relating to the detection of pathogens in a blood sample, in more detail.
- a blood sample is collected and diluted with the appropriate buffer solution.
- reagents for enrichment of the matrix objects are added to the sample followed by incubation of the sample with beads leading to the enrichment of said matrix objects (step 3). This step is followed by washing of the sample in step 4.
- Steps 2 to 4 are performed in the cartridge according to the invention, thereby enabling fast results using standard laboratory equipment.
- enriched matrix objects are distributed to several sample carriers, followed by the addition of reagents for the qPCR (step 6).
- step 9 After qPCR (step 7) and quantification of the target objects (step 8), the results are analyzed, i.e. evaluated (step 9).
- the final analysis of the target objects performed in the evaluation procedure may be carried out automatically using software enabling, e.g., the comparison of the results obtained with one or more databases.
- recommendations for therapy may be provided by such software, especially directly from guidelines or through adaptive or self-learning procedures.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
- This application is a continuation in part of PCT/EP2018/000144 filed Apr. 4, 2018, which claims priority to German application DE 102017003312.9 filed Apr. 5, 2017.
- Especially at low concentrations (especially smaller than 1000 cells per ml whole blood) of the target objects to be analyzed in whole blood, a limitation of the detection limit (especially the sensitivity and specificity) of the detection methods becomes apparent.
- For this reason, established methods aim to prepare the sample material as completely as possible in order to provide as much analyte as possible for the detection procedure (Banada et al. 2012).
- In addition, technologies have been developed that can be used to specifically enrich the target objects or the whole blood molecules contained in them. The “Cell Collector” from Gilupi, Potsdam, is a device for enriching circulating tumour cells in vivo on the surface of a metal rod. MagNA Lyser beads from Roche Diagnostics, Mannheim, are ceramic magnetobeads for the mechanical disruption of cells and the subsequent enrichment of the DNA they contain. Similarly, the beads of the μMACS series from Miltenyi, Bergisch-Gladbach are used for the enrichment of DNA and RNA from cells. This procedure may increase the sensitivity and specificity of the detection. However, these procedures are time consuming and they usually require much equipment. In addition, these methods are usually based on individual molecular target structures that are characteristic of the target objects. This means that target objects or their molecules are specifically enriched depending on the capture structures used, for example antibodies. For example, the use of antibodies to enrich a particular pathogen species may not enrich other simultaneously occurring pathogens.
- In addition, technologies have been developed to increase specificity by enriching isolated target DNA from the analysed whole blood samples. The VYOO platform of Analytik Jena, Jena, Germany, uses affinity chromatography with an immobilized protein derived from
CXXC scavenger protein 1 to specifically enrich the DNA of pathogens (Popp et al., 2015). One disadvantage of this method is the time consuming preparation (hands-on time). - Especially for the detection of pathogens in low concentrations in whole blood, non-molecular, state of the art methods comprise blood culture, in which the pathogens are cultivated for a few hours or even days before detection in order to increase the sensitivity of the detection, are therefore often preferred. This cultivation can also be preceded by molecular detection. In any case, these cultivation methods are time-consuming, labor-intensive, and problematic in that not all pathogens in the blood culture can be cultivated or multiplied and detected equally (Striebel, 2014, Thalhammer et al, 2016). This results in limited sensitivity or specificity.
- The disadvantage of all methods in the state of the art is that they are far too slow in practical application. However, in the case of the detection of pathogens in the clinical picture, for example sepsis or endocarditis, rapid analysis is crucial for successful therapy (Afshari et al., 2012). The high equipment and logistics effort, and the complexity of the described methods require that the test can only be reliably carried out by especially qualified employees with laboratory experience and therefore not or not safely at the point-of-care. Instead, the samples are taken to central laboratories where they are analysed. As a consequence, the time from the patient to the addressee of the test results, especially the attending physician, are usually too long, especially outside regular working hours (Afshari et al., 2012).
-
FIG. 1 : Representation of the general workflow for the purification of matrix objects and detection of target structures. -
FIG. 2 : Representation of the proposed workflow according to the invention, for enrichment of matrix objects and detection of pathogens. -
FIG. 3 : Representation of the proposed workflow according to the invention in detail. - The invention concerns a method and a device for enriching cells, cell fragments and molecules from whole blood for a specific detection of at least one population of cells, cell fragments or molecules contained therein.
- Cells according to the invention are biological cells, eukaryotic and prokaryotic cells, nucleated or non-nucleated, as well as unicellular organisms, and multicellular organisms. Cell fragments according to the invention are parts of cells, including cell wall components, organelles, membrane components, blood platelets and micelles, as well as viruses. Molecules according to the invention include macromolecules including proteins, peptides, and oligonucleotides such as DNA and RNA, or lipids, carbohydrates, and small molecules.
- Cells or viruses to be detected are hereinafter referred to as target objects. Pathogens such as bacteria, fungi, protozoa and viruses may also be target objects. Moreover, fetal cells in the maternal blood or circulating tumour cells may also be targets. The detection method may aim at detecting the DNA, RNA or antigens of the target objects, fragments of the cells, or the whole cells. To simplify matters, these detection methods are also referred to below as detection method of target objects.
- Cells that occur jointly with the target cells in whole blood are hereinafter referred to as matrix objects. Matrix cells comprise in particular the various types of immune cells (lymphocytes) as well as erythrocytes and cell fragments such as platelets.
- Methods for detecting target objects, their molecules and in particular their DNA from whole blood comprise, for example, molecular biological techniques such as PCR (polymerase chain reaction) or arrays, recently also sequencing, NMR or mass spectroscopy.
- The primary object of the current invention is to detect a wide spectrum of target objects including their molecules simply, quickly and yet sensitively and specifically from whole blood.
- Surprisingly, it was found that even with incomplete quantitative sample preparation a specific and sensitive detection of target objects can be achieved if only a few populations, especially individual populations of matrix objects of whole blood are enriched prior to sample preparation. This is surprising above all because it is argued in the state of the art that sensitivity and specificity depends primarily on the complete sample processing of the target objects (Banada et al., 2012).
- For example, in the case of pathogen infections in whole blood, just a few pathogens (3-1000 pathogens/ml whole blood) can be reliably, specifically and sensitively detected by PCR by enriching matrix objects, in particular immune cells or individual immune cell populations, sample processing, DNA isolation and subsequent PCR. Possibly a specific binding of the matrix objects to target objects such as pathogens or specific phagocytosis processes are associated with this. These effects could increase the ratio of pathogen to eukaryotic material and thus reduce the background signal in some detection methods, especially PCR (Loonen et al, 2013). It is already known that a nested PCR is suitable for the detection of Staphylococcus aureus from lymphocytes which are isolated with CD45-labelled magnetic beads and subsequently centrifuged. However, CD45 binds to all lymphocytes and not specifically to individual populations (Banada et al. 2012). Compared to direct PCR from whole blood, however, this method shows no sensitivity advantage and is technically complex due to the use of a centrifuge. The process is also complex and requires many individual steps. The Polaris method (Loonen et al., 2013) also requires centrifugation and several complex single steps.
- In the method according to the invention, the matrix objects can be enriched using particles that bind specifically or non-specifically to specific matrix objects. The binding of the particles to the matrix objects can be mediated by coating or coupling the particles with capture molecules, in particular antibodies or other proteins, peptides or aptamers. The particles may have other properties such as magnetic, acoustic or dielectric properties that allow them to be directly enriched or isolated. In another embodiment of the method according to the invention, the size of particles can lie within a specific range so that they can be enriched with a particle filter.
- However, the enrichment can also be carried out chromatographically, even if the device requires more complex equipment. In this embodiment, the matrix objects flow past the immobilized beads, especially beads with capture molecules, with which the surface of a flow device is coated. The described beads can also be used as packing material of a chromatographic column. An additional centrifugation step can further improve the enrichment, but increases the complexity of the process. Therefore it can be advantageous to carry out the enrichment without centrifugation step.
- The enrichment can also be done with a flow cytometer.
- It may be preferable to remove the target objects from the matrix objects before detection.
- Matrix objects that can be enriched according to the invention include leukocytes, in particular monocytes, macrophages, B cells, T cells, NK cells, eosinophilic, basophilic and neutrophil granulocytes, dendritic cells, but also erythrocytes. Matrix objects can also be natural cell fragments, including platelets, or cell debris caused by mechanical or chemical action or biological processes such as apoptosis. It may be preferable to enrich more than one population of matrix objects, in particular by using particles or beads specific to several matrix objects or different particles specific to one type of matrix object. However, the accumulation of the entire lymphocyte spectrum is apparently unfavourable (Banada et al., 2012).
- The enrichment of the immune cells of the example of an embodiment of the invention is advantageous, for example, via antibodies that are bound to a carrier system (especially particles, especially beads, or solid matrices). Similarly advantageous is to perform the enrichment in fluidic or microfluidic systems, in which the immune cells or particles are enriched by forces or energy input, especially by acoustic or dielectrophoretic effects in the liquid flow, or in the flow cytometer.
- It may be advantageous to histologically examine the matrix objects together with the target objects and preferably to analyse them by fluorescence in situ hybridisation or antibody staining.
- It can also be advantageous to lyse the enriched matrix objects and thus release the nucleic acids, in particular DNA and RNA of the target objects and in particular the pathogens. Various state-of-the-art processes are available for this purpose, including trizollysis, other chemical methods and mechanical digestion. Subsequent precipitation of the DNA or RNA with ethanol and purification via columns are often advantageous.
- PCR, isothermal amplification, sequencing or array-based methods are suitable for the detection of DNA or RNA. multiplex and single PCR can be distinguished in PCR, the latter of which is particularly advantageous because it enables a particularly simple procedure. This makes individual PCR particularly suitable for carrying out the procedure at the point of care and detecting specific pathogens and resistance indicators or genes.
- The invention also includes a device for isolation, optionally supplemented by the detection of target objects.
- In a specific example of an embodiment of the invention, a cartridge system comprises devices for sample introduction, storage locations for different wash buffers, storage locations for a bead-antibody system for binding specific matrix objects, in particular immune cells, as well as a possibility for lysis of isolated matrix objects, and optionally a device for extracting the RNA or DNA. In the cartridge system, the antibody bead system is added to the whole blood, washed with a wash buffer, the antibody bead system with bound matrix objects is isolated via a sieve system or magnetically, mixed with cell lysis buffer and the precipitated DNA removed. In this cartridge system a fast and simple enrichment of the matrix objects as well as lysis and DNA isolation is carried out in an almost closed container, thus reducing the risk of contamination of the sample with foreign DNA.
- In a further embodiment, the RNA or DNA remains in the cartridge system and is not removed. Instead, PCR is performed through a window in the cartridge or with integrated heating and detection elements inside the cartridge. It then contains another storage location for the PCR reagents.
- In a further specific example of an embodiment of the invention, the isolated DNA is applied directly to a PCR analysis plate, which contains all chemicals for the analysis of various pathogens in a standardised form. This plate can be produced as multiplex PCR or as a set of single PCR performed in parallel.
- The isolated DNA from the cartridge can be applied manually and especially with a pipette or directly from the cartridge via a special dosing system.
- DNA lysis in the cartridge and subsequent PCR is only one possibility for analysis; further examples for embodiments performing cell analysis include spectroscopic, enzymatic, colorimetric, histological, chemical-analytical (especially MALDI-TOF-MS), electrochemical and other physical methods (especially NMR).
- Furthermore, it can be advantageous to carry out the evaluation of the analysis procedure automatically using software and to compare results with a database and to derive recommendations for therapy, especially directly from guidelines or through adaptive or self-learning procedures.
- The process according to the invention, the device according to the invention, and the application kit according to the invention can be used for the detection of a variety of diseases and physiological conditions. These include the following examples:
- In the case of Systemic Inflammatory Response Syndrome (SIRS), immediate evidence is of interest as to whether the symptoms observed in the patient are caused by sepsis, i.e. pathogens in the blood stream, or by other causes. Pathogenic viruses, bacteria, fungi or parasites can be detected according to the invention. This proof enables the treating physician to initiate a better antibiotic or anti-pathogen therapy with optimal medication.
- Endocarditis also requires the rapid detection of pathogens in the blood for a therapeutic decision. In endocarditis in particular, the conditions for blood culture are considered particularly demanding and time-consuming. (Durack et al. 1994). Pathogens that grow particularly slowly in the laboratory but are relevant for about 3% of endocarditis cases are grouped in the HACEK group (Aggregatibacter aphrophrophilus, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae).
- In the case of pneumonia, bacteria can be detected in the urine after a few days. State-of-the-art blood cultures are recommended, especially for nocosomial pneumonia and pneumonia caused by air conditioning systems, which is becoming increasingly common. The method according to the invention also offers the advantage of a faster detection of these infections. Zoonoses are infections with a wide range of manifestations, some of which are diagnosed using blood cultures, some of which last 4-6 weeks, for example when brucellosis is suspected. The method according to the invention also offers the advantage of a faster detection of these infections.
- Due to its specific enrichment, the ingenious method also has potential applications for viral diseases, especially for detection of HIV in pregnant women, where a reliable diagnosis is particularly important in order to initiate measures to prevent transmission to the child.
- The invention-based method can also be used in the quality and follow-up of CAR-T therapies (Chimeric Antigen Receptor T-cell therapies).
- In a specific embodiment, the procedure according to the invention comprises the following steps: First, one or more blood samples are taken from the patient, the coagulation of which is avoided in the EDTA/citrate buffer. Beads, for example anti-CD14 beads from pluriSelect, are added to this sample to bind the matrix objects, for example all CD14-bearing cells such as monocytes and macrophages.
- The beads are then separated by a sieve, for example with the Cell Strainer from pluriSelect. The sample with the enriched matrix objects is subjected to DNA lysis in a subsequent step (e.g. tricol precipitation). The sample is then distributed to several sample vessels, for example wells of a-microtiter plate suitable for qPCR. These wells already contain reagents for a qPCR, including primers for a known sequence which are different for each well, and which serves to identify a target object or its resistance to therapy via a genetic marker. Subsequently a single qPCR is performed. Quantification of the signal makes it possible to determine which target objects or resistance genes are present in the sample.
- The use of conventional PCR with subsequent gel electrophoresis for the detection of PCR fragments can also be advantageous, just like multiplex PCR.
- The invention also comprises an application kit for isolation and analysis of cells, cell fragments and molecules, consisting of at least
-
- at least one cartridge for isolating matrix objects from whole blood, which can optionally be extended by the capability of DNA isolation
- a sample carrier for the detection, in particular a PCR sample carrier and in particular a PCR sample plate, which contains all reagents for the detection and in particular for carrying out a PCR and the detection of target objects, for example pathogens and optionally their resistances
- dilution and reaction buffer
- one or more probes or syringes with cannula and other necessary materials
- a protocol for application.
- The invention is explained in more detail below using the example embodiments shown in the drawings:
-
FIG. 1 shows the process sequence according to the method of invention. Matrix objects associated with target structures are specifically isolated from a sample. After processing the samples, the actual detection method of the target structures is carried out. -
FIG. 2 shows a specific procedure according to the invention for the detection of pathogens in blood. EDTA whole blood is introduced into the cartridge system according to invention, in which the sample is incubated with CD14 beads, washed with buffer and transferred via a sieve system isolating the beads together with trapped monocytes/macrophage (matrix objects) and the pathogens (target objects) contained therein. Cell lysis and isolation/purification of the DNA is then carried out before the DNA sample is transferred with pipettes from the cartridge into the PCR well plates according to the invention. These plates already contain all the chemicals required for PCR in lyophilized form; the polymerase is added to the well plate together with the DNA sample. Subsequently, PCR and thus specific detection of the pathogens is performed. The enrichment of the target objects with the matrix objects or the depletion of non-target objects allows for an increased sensitivity and specificity of the detection method compared to the state of the art; employing the workflow according to the invention and the cartridge system leads to fast results using standard laboratory equipment. -
FIG. 3 shows the procedure exemplified inFIG. 2 , relating to the detection of pathogens in a blood sample, in more detail. In a first step, a blood sample is collected and diluted with the appropriate buffer solution. In a second step, reagents for enrichment of the matrix objects are added to the sample followed by incubation of the sample with beads leading to the enrichment of said matrix objects (step 3). This step is followed by washing of the sample in step 4.Steps 2 to 4 are performed in the cartridge according to the invention, thereby enabling fast results using standard laboratory equipment. In step 5, enriched matrix objects are distributed to several sample carriers, followed by the addition of reagents for the qPCR (step 6). After qPCR (step 7) and quantification of the target objects (step 8), the results are analyzed, i.e. evaluated (step 9). The final analysis of the target objects performed in the evaluation procedure may be carried out automatically using software enabling, e.g., the comparison of the results obtained with one or more databases. Furthermore, recommendations for therapy may be provided by such software, especially directly from guidelines or through adaptive or self-learning procedures. -
- Popp et al. 2015: J. Popp, M. Bauer: “Modern Techniques for Pathogen Detection”, John Wiley & Sons, 23 Feb. 2015, p. 86
- Streibel 2014: H.-W. Striebel: “Operative Intensivmedizin: Sicherheit in der klinischen Praxis”, Schattauer Verlag, 6 Oct. 2014, p. 869
- Thalhammer et al. 2016: F. Thalhammer, P. Apfalter, M. Frick, H. Gabriel, R. Gattringer, A. Grisold, R. Krause, Ch. Loewe, L. Müller, H. J. Nesser, A. Wechsler-Fördös, G. Weiss, Ch. Wenisch, S. Winkler, A. Zuckermann, R. Zweiker, K. Huber: “Die infektiöse Endokarditis” Österreichische Ärztezeitung, Supplementum, August 2016, p. 2
- Afshari et al., 2012: A. Afshari, J. Schrenzel, M. Ieven, St. Harbarth “Bench-to-bedside review: Rapid molecular disgnostics for bloodstream infection—a new frontier?” Crit Care. 2012; 16(3): 222. Published online 2012 May 29. doi: 10.1186/cc11202
- Banada et al. 2012: P. P. Banada, S. Chakravorty, D. Shah, M. Burday, F. M. Mazzella, D. Alland: “Highly Sensitive Detection of Staphylococcus aureus Directly from Patient Blood” PLOS one, 17 Feb. 2012 http://dx.doi.org/10.1371/journal.pone.0031126
- Loonen et al., 2013: A. J. M. Loonen, M. P. Bos, B. van Meerbergen, S. Neerken, A. Catsburg, I. Dobbelaer, R. Penterman, G. Maertens, P. van de Wiel, P. Savelkoul, A. J. C. van den Brule: “Comparison of Pathogen DNA Isolation Methods from Large Volumes of Whole Blood to Improve Molecular Diagnosis of Bloodstream Infections” August 2013, http://dx.doi.org/10.1371/journal.pone.0072349
- Durack et al. 1994: Durack D T, Lukes A S, Bright D K “New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings.” Duke Endocarditis Service, Am J Med. 1994 March; 96(3):200-9.
Claims (13)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/185,544 US20230251242A1 (en) | 2017-04-05 | 2023-03-17 | Detection Method and Device |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017003312.9 | 2017-04-05 | ||
| DE102017003312.9A DE102017003312A1 (en) | 2017-04-05 | 2017-04-05 | Detection method and device |
| PCT/EP2018/000144 WO2018184719A1 (en) | 2017-04-05 | 2018-04-04 | Detection method and device |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2018/000144 Continuation-In-Part WO2018184719A1 (en) | 2017-04-05 | 2018-04-04 | Detection method and device |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18/185,544 Continuation-In-Part US20230251242A1 (en) | 2017-04-05 | 2023-03-17 | Detection Method and Device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20200032318A1 true US20200032318A1 (en) | 2020-01-30 |
| US11629374B2 US11629374B2 (en) | 2023-04-18 |
Family
ID=62044643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/592,992 Active 2038-07-29 US11629374B2 (en) | 2017-04-05 | 2019-10-04 | Detection method and device |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11629374B2 (en) |
| EP (1) | EP3607094A1 (en) |
| DE (1) | DE102017003312A1 (en) |
| WO (1) | WO2018184719A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102017003312A1 (en) | 2017-04-05 | 2018-10-11 | Rolf Günther | Detection method and device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2097952C (en) * | 1993-06-08 | 2006-03-14 | Alex D. Romaschin | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
| AU2002326659A1 (en) * | 2001-08-16 | 2003-03-24 | Millipore Corporation | Holder for multiple well sequencing / pcr plate |
| US20110195437A1 (en) * | 2008-08-04 | 2011-08-11 | Synmed Research Gmbh | Method for characterizing, in particular for quantifying, molecular markers that are intracellularly absorbed from tissues by blood macrophages that are recirculated from the tissues into the circulatory system |
| WO2013091102A1 (en) * | 2011-12-21 | 2013-06-27 | Geneohm Sciences Canada Inc. | Enrichment & isolation of microbial cells & microbial nucleic acids from a biological sample |
| US20170151561A1 (en) * | 2014-06-26 | 2017-06-01 | Corning Incorporated | Reinforced microplate |
| DE102017003312A1 (en) | 2017-04-05 | 2018-10-11 | Rolf Günther | Detection method and device |
-
2017
- 2017-04-05 DE DE102017003312.9A patent/DE102017003312A1/en not_active Withdrawn
-
2018
- 2018-04-04 WO PCT/EP2018/000144 patent/WO2018184719A1/en not_active Ceased
- 2018-04-04 EP EP18719437.8A patent/EP3607094A1/en active Pending
-
2019
- 2019-10-04 US US16/592,992 patent/US11629374B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Gibellini et al., "Simultaneous detection of HCV and HIV-1 by SYBR Green real time multiplex RT-PCR technique in plasma samples," Molecular and Cellular Probes, vol. 20, pages 223-229. (Year: 2006) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3607094A1 (en) | 2020-02-12 |
| US11629374B2 (en) | 2023-04-18 |
| WO2018184719A1 (en) | 2018-10-11 |
| DE102017003312A1 (en) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12038437B2 (en) | Reagents, methods and kits for diagnosing primary immunodeficiencies | |
| US9429520B2 (en) | Enrichment and identification of fetal cells in maternal blood and ligands for such use | |
| JP4151986B2 (en) | Method for measuring lymphocyte function | |
| US20090081689A1 (en) | Reagents and methods to enrich rare cells from body fluids | |
| US20200132682A1 (en) | Methods and kits for exosome isolation and quantification | |
| JP2011508892A (en) | Method for isolation and enumeration of cells from a composite sample matrix | |
| Rahmanian et al. | Cell separation: Potentials and pitfalls | |
| JP6312835B2 (en) | Method for sorting nucleated red blood cells | |
| CN115166252A (en) | Lymphocyte subgroup classification and quantitative detection kit, detection method and application thereof | |
| Murray et al. | Unsupervised capture and profiling of rare immune cells using multi-directional magnetic ratcheting | |
| CN106544411A (en) | A kind of method for identifying mammal y sperm typing using mark analysis of protein | |
| Koo et al. | Sorting single T cells based on secreted cytokines and surface markers using hydrogel nanovials | |
| US11629374B2 (en) | Detection method and device | |
| CN117347633A (en) | Application of CD45+CD8+HLA-DRB5+T cells in the preparation of kits for assisting diagnosis of aplastic anemia and graft-versus-host disease | |
| US20230251242A1 (en) | Detection Method and Device | |
| Genshaft et al. | Clinical implementation of single-cell RNA sequencing using liver fine needle aspirate tissue sampling and centralized processing captures compartment specific immuno-diversity | |
| JPH10507632A (en) | Concentration of fetal blood from the mother | |
| Yano et al. | DNA extraction for short tandem repeat typing from mixed samples using anti-human leukocyte CD45 and ABO blood group antibodies | |
| Reed et al. | Sample suitability for the detection of minor white cell populations (microchimerism) by polymerase chain reaction | |
| Fuss | Purification of T cell populations | |
| CA3134973A1 (en) | Lyophilized antibody panel | |
| US20020019004A1 (en) | Method for isolating molecules, cells and other particles which are specifically bound to a large particle | |
| Strauss-Albee et al. | CyTOF: single cell mass cytometry for evaluation of complex innate cellular phenotypes | |
| CN119777000A (en) | A method for constructing a single-cell transcriptome sequencing library for high-throughput sequencing and its application | |
| CN120594847A (en) | A method for simultaneously identifying cell subpopulations and related factor phosphorylation levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |